Advertisement

Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder

      Background

      Treatment adherence is a significant problem in patients with bipolar disorder. This study was designed to determine the efficacy of risperidone long-acting injectable (LAI) in the maintenance treatment of bipolar I disorder.

      Methods

      Eligible patients with current or recent manic or mixed episodes (n = 559, aged 18–65 years) were treated with open-label oral risperidone for 3 weeks (period II) and open-label risperidone LAI for 26 weeks (n = 501; period III). Patients who maintained response (n = 303) were randomly allocated 1:1 to placebo injections (n = 149) or to continue risperidone LAI (n = 154) for up to 24 months (period IV).

      Results

      Most (77%) patients on risperidone LAI received a dose of 25 mg every 2 weeks during period IV. Time to recurrence for any mood episode (primary outcome variable) was significantly longer in the risperidone LAI group versus placebo (p < .001); the difference was significant for time to recurrence of elevated-mood episode (p < .001) but not time to recurrence of depressive episode (p = .805). Weight gains ≥7% (compared with the period's baseline) occurred in 15% of patients in period III; in 12% of patients on risperidone LAI and 3% of patients on placebo in period IV.

      Conclusions

      Risperidone LAI monotherapy significantly delayed the time to recurrence of mood episodes, versus placebo, in this controlled, randomized study in patients with bipolar I disorder. Risperidone LAI was tolerable and no new safety concerns emerged compared with previous studies of risperidone LAI.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goodwin F.K.
        • Jamison K.R.
        Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression.
        2nd ed. Oxford University Press, New York2007
        • Post R.M.
        Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena.
        Neurosci Biobehav Rev. 2007; 31: 858-873
        • Simon G.E.
        Social and economic burden of mood disorders.
        Biol Psychiatry. 2003; 54: 208-215
        • Goetzel R.Z.
        • Hawkins K.
        • Ozminkowski R.J.
        • Wang S.
        The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large US employers in 1999.
        J Occup Environ Med. 2003; 45: 5-14
        • Yatham L.N.
        Atypical antipsychotics for bipolar disorder.
        Psychiatr Clin North Am. 2005; 28: 325-347
        • Derry S.
        • Moore R.A.
        Atypical antipsychotics in bipolar disorder: Systematic review of randomised trials.
        BMC Psychiatry. 2007; 7: 40
        • Sajatovic M.
        • Valenstein M.
        • Blow F.C.
        • Ganoczy D.
        • Ignacio R.V.
        Treatment adherence with antipsychotic medications in bipolar disorder.
        Bipolar Disord. 2006; 8: 232-241
        • Sajatovic M.
        • Davies M.
        • Hrouda D.R.
        Enhancement of treatment adherence among patients with bipolar disorder.
        Psychiatr Serv. 2004; 55: 264-269
        • Chue P.
        • Emsley R.
        Long-acting formulations of atypical antipsychotics: Time to reconsider when to introduce depot antipsychotics.
        CNS Drugs. 2007; 21: 441-448
        • McEvoy J.P.
        Risks versus benefits of different types of long-acting injectable antipsychotics.
        J Clin Psychiatry. 2006; 67: 15-18
        • Yatham L.N.
        • Fallu A Binder C.E.
        A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder.
        Acta Psychiatr Scand Suppl. 2007; 434: 50-56
        • Han C.
        • Lee M.S.
        • Pae C.U.
        • Ko Y.H.
        • Patkar A.A.
        • Jung I.K.
        Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder.
        Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 1219-1223
        • Malempati R.N.
        • Bond D.J.
        • Yatham L.N.
        Depot risperidone in the outpatient management of bipolar disorder: A 2-year study of 10 patients.
        Int Clin Psychopharmacol. 2008; 23: 88-94
        • Macfadden W.
        • Alphs L.
        • Haskins J.T.
        • Turner N.
        • Turkoz I.
        • Bossie C.
        • et al.
        A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
        Bipolar Disord. 2009; 11: 827-839
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders.
        4th ed. American Psychiatric Publishing, Washington, DC2000
        • Young R.C.
        • Biggs J.T.
        • Ziegler V.E.
        • Meyer D.A.
        A rating scale for mania: Reliability, validity and sensitivity.
        Br J Psychiatry. 1978; 133: 429-435
        • Montgomery S.A.
        • Asberg M.
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Guy W.
        ECDEU Assessment Manual for Psychopharmacology.
        in: National Institute of Mental Health, US Department Health, Education and Welfare, Rockville, MD1976: 218-222 (Publication ADM 76-338)
        • Martinez-Aran A.
        • Vieta E.
        • Chengappa K.N.
        • Gershon S.
        • Mullen J.
        • Paulsson B.
        Reporting outcomes in clinical trials for bipolar disorder: A commentary and suggestions for change.
        Bipolar Disord. 2008; 10: 566-579
        • O'Brien P.C.
        • Fleming T.R.
        A multiple testing procedure for clinical trials.
        Biometrics. 1979; 35: 549-556
        • Hwang I.K.
        • Shih W.J.
        • De Cani J.S.
        Group sequential designs using a family of type I error probability spending functions.
        Stat Med. 1990; 9: 1439-1445
        • Sharma V.
        • Yatham L.N.
        • Haslam D.R.
        • Silverstone P.H.
        • Parikh S.V.
        • Matte R.
        • et al.
        Continuation and prophylactic treatment of bipolar disorder.
        Can J Psychiatry. 1997; 42: 92S-100S
        • Esparon J.
        • Kolloori J.
        • Naylor G.J.
        • McHarg A.M.
        • Smith A.H.
        • Hopwood S.E.
        Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients.
        Br J Psychiatry. 1986; 148: 723-725
        • Tohen M.
        • Calabrese J.R.
        • Sachs G.S.
        • Banov M.D.
        • Detke H.C.
        • Risser R.
        • et al.
        Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
        Am J Psychiatry. 2006; 163: 247-256
        • Keck Jr, P.E.
        • Calabrese J.R.
        • McIntyre R.S.
        • McQuade R.D.
        • Carson W.H.
        • Eudicone J.M.
        • et al.
        Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo.
        J Clin Psychiatry. 2007; 68: 1480-1491
        • EMEA Committee for Proprietary Medicinal Products
        Note for guidance on clinical investigation of medical products in the treatment and prevention of bipolar disorder.
        (Accessed November 17, 2009)
        • Geddes J.R.
        • Burgess S.
        • Hawton K.
        • Jamison K.
        • Goodwin G.M.
        Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials.
        Am J Psychiatry. 2004; 161: 217-222
        • Calabrese J.R.
        • Vieta E.
        • El-Mallakh R.
        • Findling R.L.
        • Youngstrom E.A.
        • Elhaj O.
        • et al.
        Mood state at study entry as predictor of the polarity of relapse in bipolar disorder.
        Biol Psychiatry. 2004; 56: 957-963
        • Kane J.M.
        • Eerdekens M.
        • Lindenmayer J.P.
        • Keith S.J.
        • Lesem M.
        • Karcher K.
        Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic.
        Am J Psychiatry. 2003; 160: 1125-1132
        • Fleischhacker W.W.
        • Eerdekens M.
        • Karcher K.
        • Remington G.
        • Llorca P.M.
        • Chrzanowski W.
        • et al.
        Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic.
        J Clin Psychiatry. 2003; 64: 1250-1257
        • Chue P.
        • Eerdekens M.
        • Augustyns I.
        • Lachaux B.
        • Molcan P.
        • Eriksson L.
        • et al.
        Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
        Eur Neuropsychopharmacol. 2005; 15: 111-117
        • Simpson G.M.
        • Mahmoud R.A.
        • Lasser R.A.
        • Kujawa M.
        • Bossie C.A.
        • Turkoz I.
        • et al.
        A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
        J Clin Psychiatry. 2006; 67: 1194-1203
        • Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc
        RISPERDAL CONSTA Highlights of Prescribing Information.
        (Accessed April 6, 2009)
        • Nasrallah H.A.
        • Lasser R.
        Improving patient outcomes in schizophrenia: Achieving remission.
        J Psychopharmacol. 2006; 20: 57-61
        • Olivares J.M.
        • Rodriguez-Morales A.
        • Diels J.
        • Povey M.
        • Jacobs A.
        • Zhao Z.
        • et al.
        Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
        Eur Psychiatry. 2009; 24: 287-296